Cargando…

Combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study

BACKGROUND: Intra-abdominal candidiasis (IAC) is difficult to predict in critically ill patients with intra-abdominal infection, leading to the overuse of antifungal treatments. Serum and peritoneal 1.3-beta-d-glucan (sBDG and pBDG) have been proposed to confirm or invalidate the diagnosis of IAC, b...

Descripción completa

Detalles Bibliográficos
Autores principales: Novy, Emmanuel, Rivière, Jérémie, Nguyen, Maxime, Arfeuille, Gaëlle, Louis, Guillaume, Bouhemad, Bélaïd, Pottecher, Julien, Hecketsweiler, Stéphane, Germain, Adeline, Laithier, François-Xavier, Losser, Marie-Reine, Debourgogne, Anne, Bernard, Yohann, Rousseau, Hélène, Baumann, Cédric, Luc, Amandine, Birckener, Julien, Machouart, Marie-Claire, Guerci, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691030/
https://www.ncbi.nlm.nih.gov/pubmed/38037130
http://dx.doi.org/10.1186/s13054-023-04761-7
_version_ 1785152652740395008
author Novy, Emmanuel
Rivière, Jérémie
Nguyen, Maxime
Arfeuille, Gaëlle
Louis, Guillaume
Bouhemad, Bélaïd
Pottecher, Julien
Hecketsweiler, Stéphane
Germain, Adeline
Laithier, François-Xavier
Losser, Marie-Reine
Debourgogne, Anne
Bernard, Yohann
Rousseau, Hélène
Baumann, Cédric
Luc, Amandine
Birckener, Julien
Machouart, Marie-Claire
Guerci, Philippe
author_facet Novy, Emmanuel
Rivière, Jérémie
Nguyen, Maxime
Arfeuille, Gaëlle
Louis, Guillaume
Bouhemad, Bélaïd
Pottecher, Julien
Hecketsweiler, Stéphane
Germain, Adeline
Laithier, François-Xavier
Losser, Marie-Reine
Debourgogne, Anne
Bernard, Yohann
Rousseau, Hélène
Baumann, Cédric
Luc, Amandine
Birckener, Julien
Machouart, Marie-Claire
Guerci, Philippe
author_sort Novy, Emmanuel
collection PubMed
description BACKGROUND: Intra-abdominal candidiasis (IAC) is difficult to predict in critically ill patients with intra-abdominal infection, leading to the overuse of antifungal treatments. Serum and peritoneal 1.3-beta-d-glucan (sBDG and pBDG) have been proposed to confirm or invalidate the diagnosis of IAC, but clinical studies have reported inconsistent results, notably because of heterogeneous populations with a low IAC prevalence. This study aimed to identify a high-risk IAC population and evaluate pBDG and sBDG in diagnosing IAC. METHODS: This prospective multicenter noninterventional French study included consecutive critically ill patients undergoing abdominal surgery for abdominal sepsis. The primary objective was to establish the IAC prevalence. The secondary objective was to explore whether sBDG and pBDG could be used to diagnose IAC. Wako(®) beta-glucan test (WT, Fujifilm Wako Chemicals Europe, Neuss, Germany) was used for pBDG measurements. WT and Fungitell(®) beta-d-glucan assay (FA, Associate of Cape Cod, East Falmouth, USA) were used for sBDG measurements. RESULTS: Between 1 January 2020 and 31 December 2022, 199 patients were included. Patients were predominantly male (63%), with a median age of 66 [54–72] years. The IAC prevalence was 44% (87/199). The main IAC type was secondary peritonitis. Septic shock occurred in 63% of cases. After multivariate analysis, a nosocomial origin was associated with more IAC cases (P = 0.0399). The median pBDG level was significantly elevated in IAC (448 [107.5–1578.0] pg/ml) compared to non-IAC patients (133 [16.0–831.0] pg/ml), P = 0.0021. For a pBDG threshold of 45 pg/ml, the negative predictive value in assessing IAC was 82.3%. The median sBDG level with WT (n = 42) at day 1 was higher in IAC (5 [3.0–9.0] pg/ml) than in non-IAC patients (3 [3.0–3.0] pg/ml), P = 0.012. Similarly, median sBDG level with FA (n = 140) at day 1 was higher in IAC (104 [38.0–211.0] pg/ml) than in non-IAC patients (50 [23.0–141.0] pg/ml), P = 0.009. Combining a peritonitis score < 3, sBDG < 3.3 pg/ml (WT) and pBDG < 45 pg/ml (WT) yielded a negative predictive value of 100%. CONCLUSION: In critically ill patients with intra-abdominal infection requiring surgery, the IAC prevalence was 44%. Combining low sBDG and pBDG with a low peritonitis score effectively excluded IAC and could limit unnecessary antifungal agent exposure. Trial registration: The study was registered with ClinicalTrials.gov (ID number 03997929, first registered on June 24, 2019). GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-023-04761-7.
format Online
Article
Text
id pubmed-10691030
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106910302023-12-02 Combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study Novy, Emmanuel Rivière, Jérémie Nguyen, Maxime Arfeuille, Gaëlle Louis, Guillaume Bouhemad, Bélaïd Pottecher, Julien Hecketsweiler, Stéphane Germain, Adeline Laithier, François-Xavier Losser, Marie-Reine Debourgogne, Anne Bernard, Yohann Rousseau, Hélène Baumann, Cédric Luc, Amandine Birckener, Julien Machouart, Marie-Claire Guerci, Philippe Crit Care Research BACKGROUND: Intra-abdominal candidiasis (IAC) is difficult to predict in critically ill patients with intra-abdominal infection, leading to the overuse of antifungal treatments. Serum and peritoneal 1.3-beta-d-glucan (sBDG and pBDG) have been proposed to confirm or invalidate the diagnosis of IAC, but clinical studies have reported inconsistent results, notably because of heterogeneous populations with a low IAC prevalence. This study aimed to identify a high-risk IAC population and evaluate pBDG and sBDG in diagnosing IAC. METHODS: This prospective multicenter noninterventional French study included consecutive critically ill patients undergoing abdominal surgery for abdominal sepsis. The primary objective was to establish the IAC prevalence. The secondary objective was to explore whether sBDG and pBDG could be used to diagnose IAC. Wako(®) beta-glucan test (WT, Fujifilm Wako Chemicals Europe, Neuss, Germany) was used for pBDG measurements. WT and Fungitell(®) beta-d-glucan assay (FA, Associate of Cape Cod, East Falmouth, USA) were used for sBDG measurements. RESULTS: Between 1 January 2020 and 31 December 2022, 199 patients were included. Patients were predominantly male (63%), with a median age of 66 [54–72] years. The IAC prevalence was 44% (87/199). The main IAC type was secondary peritonitis. Septic shock occurred in 63% of cases. After multivariate analysis, a nosocomial origin was associated with more IAC cases (P = 0.0399). The median pBDG level was significantly elevated in IAC (448 [107.5–1578.0] pg/ml) compared to non-IAC patients (133 [16.0–831.0] pg/ml), P = 0.0021. For a pBDG threshold of 45 pg/ml, the negative predictive value in assessing IAC was 82.3%. The median sBDG level with WT (n = 42) at day 1 was higher in IAC (5 [3.0–9.0] pg/ml) than in non-IAC patients (3 [3.0–3.0] pg/ml), P = 0.012. Similarly, median sBDG level with FA (n = 140) at day 1 was higher in IAC (104 [38.0–211.0] pg/ml) than in non-IAC patients (50 [23.0–141.0] pg/ml), P = 0.009. Combining a peritonitis score < 3, sBDG < 3.3 pg/ml (WT) and pBDG < 45 pg/ml (WT) yielded a negative predictive value of 100%. CONCLUSION: In critically ill patients with intra-abdominal infection requiring surgery, the IAC prevalence was 44%. Combining low sBDG and pBDG with a low peritonitis score effectively excluded IAC and could limit unnecessary antifungal agent exposure. Trial registration: The study was registered with ClinicalTrials.gov (ID number 03997929, first registered on June 24, 2019). GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-023-04761-7. BioMed Central 2023-11-30 /pmc/articles/PMC10691030/ /pubmed/38037130 http://dx.doi.org/10.1186/s13054-023-04761-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Novy, Emmanuel
Rivière, Jérémie
Nguyen, Maxime
Arfeuille, Gaëlle
Louis, Guillaume
Bouhemad, Bélaïd
Pottecher, Julien
Hecketsweiler, Stéphane
Germain, Adeline
Laithier, François-Xavier
Losser, Marie-Reine
Debourgogne, Anne
Bernard, Yohann
Rousseau, Hélène
Baumann, Cédric
Luc, Amandine
Birckener, Julien
Machouart, Marie-Claire
Guerci, Philippe
Combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study
title Combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study
title_full Combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study
title_fullStr Combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study
title_full_unstemmed Combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study
title_short Combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study
title_sort combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691030/
https://www.ncbi.nlm.nih.gov/pubmed/38037130
http://dx.doi.org/10.1186/s13054-023-04761-7
work_keys_str_mv AT novyemmanuel combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT rivierejeremie combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT nguyenmaxime combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT arfeuillegaelle combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT louisguillaume combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT bouhemadbelaid combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT pottecherjulien combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT hecketsweilerstephane combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT germainadeline combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT laithierfrancoisxavier combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT lossermariereine combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT debourgogneanne combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT bernardyohann combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT rousseauhelene combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT baumanncedric combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT lucamandine combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT birckenerjulien combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT machouartmarieclaire combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy
AT guerciphilippe combinationofserumandperitoneal13betadglucancanruleoutintraabdominalcandidiasisinsurgicalcriticallyillpatientsamulticenterprospectivestudy